LAVA Therapeutics (LVTX) has released an update.
LAVA Therapeutics N.V. held its Annual General Meeting where shareholders adopted the financial accounts for 2023, appointed PricewaterhouseCoopers as the external auditor for 2024, and granted the board authorization to issue shares and limit preemption rights. Directors were released from liability for the previous financial year, and key executive and non-executive directors were re-appointed. Additionally, amendments to the company’s articles of association were approved, allowing for potential fully virtual shareholder meetings in accordance with Dutch law.
For further insights into LVTX stock, check out TipRanks’ Stock Analysis page.
